STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event will take place at The Plaza Hotel in New York City, where CEO Dr. Dolev Rafaeli will conduct one-on-one meetings from 9:00 AM to 3:00 PM ET. Interested parties can register for meetings through John Perez at D. Boral Capital.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medica specializzata in trattamenti dermatologici, annuncia la sua partecipazione al D. Boral Capital Inaugural Global Conference che si terrà il 14 maggio 2025. L'evento avrà luogo al The Plaza Hotel di New York City, dove il CEO Dr. Dolev Rafaeli terrà incontri individuali dalle 9:00 alle 15:00 ET. Gli interessati possono registrarsi per gli incontri contattando John Perez presso D. Boral Capital.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica enfocada en tratamientos dermatológicos, anuncia su participación en la D. Boral Capital Inaugural Global Conference el 14 de mayo de 2025. El evento se llevará a cabo en The Plaza Hotel en la ciudad de Nueva York, donde el CEO, Dr. Dolev Rafaeli, realizará reuniones individuales de 9:00 a.m. a 3:00 p.m. ET. Las partes interesadas pueden registrarse para las reuniones a través de John Perez en D. Boral Capital.
STRATA Skin Sciences (NASDAQ: SSKN)은 피부과 치료에 중점을 둔 의료 기술 회사로, 2025년 5월 14일에 열리는 D. Boral Capital Inaugural Global Conference에 참여한다고 발표했습니다. 이 행사는 뉴욕시의 The Plaza Hotel에서 개최되며, CEO인 Dr. Dolev Rafaeli가 오전 9시부터 오후 3시(동부 시간)까지 일대일 미팅을 진행할 예정입니다. 관심 있는 분들은 D. Boral Capital의 John Perez를 통해 미팅 등록이 가능합니다.
STRATA Skin Sciences (NASDAQ : SSKN), une entreprise de technologie médicale spécialisée dans les traitements dermatologiques, annonce sa participation à la D. Boral Capital Inaugural Global Conference le 14 mai 2025. L'événement se tiendra au The Plaza Hotel à New York, où le PDG, Dr. Dolev Rafaeli, tiendra des rendez-vous individuels de 9h00 à 15h00 ET. Les personnes intéressées peuvent s'inscrire aux réunions via John Perez chez D. Boral Capital.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnologieunternehmen mit Schwerpunkt auf dermatologischen Behandlungen, gibt seine Teilnahme an der D. Boral Capital Inaugural Global Conference am 14. Mai 2025 bekannt. Die Veranstaltung findet im The Plaza Hotel in New York City statt, wo CEO Dr. Dolev Rafaeli von 9:00 bis 15:00 Uhr ET Einzelgespräche führen wird. Interessierte können sich für Meetings über John Perez bei D. Boral Capital anmelden.
- None.
- None.
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019.
President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
